Merck exec jumps ship to join Tilos Therapeutics

27 June 2018

Cambridge, Massachusetts-based Tilos Therapeutics, a biotech firm developing anti-LAP antibodies for the treatment of cancer, fibrosis and autoimmune diseases, today announced the appointment of Jessie English as chief scientific officer, marking yet another switch from a pharma major to a biopharma start up.

“Jessie brings to our team significant oncology leadership experience, having held a number of senior scientific positions within the biopharmaceutical industry over the past 20 years,” said Barbara Fox, founder and chief executive of Tilos. “Her energy and experience in leading discovery efforts from target identification to clinical candidate and conducting preclinical translational studies for clinical programs will be a significant asset to Tilos,” she added.

Prior to joining Tilos, Dr English served as vice president and head of discovery research immuno-oncology translational innovation platform at EMD Serono, a US unit of Merck KGaA (MRK: DE).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK